FOLFOX Can Be Given Concurrently with Radiotherapy, But This Is NOT Standard Practice for Rectal Cancer
For rectal cancer, FOLFOX is typically administered sequentially (not simultaneously) with radiotherapy as part of a total neoadjuvant therapy (TNT) approach, where chemotherapy and chemoradiotherapy are given in sequence before surgery. The standard concurrent chemoradiotherapy regimen uses fluoropyrimidine-based therapy (continuous infusion 5-FU or capecitabine), not FOLFOX 1, 2.
Standard Approach: Sequential Administration
For Locally Advanced Rectal Cancer (TNT Strategy)
The preferred modern approach involves:
- FOLFOX chemotherapy first (typically 4-6 cycles as induction)
- Followed by chemoradiotherapy with 5-FU or capecitabine concurrent with radiation
- Then surgery with total mesorectal excision
- Finally additional FOLFOX as adjuvant therapy 2, 3
Alternatively, the sequence can be reversed (chemoRT first, then FOLFOX), with similar outcomes 3.
Why Not Concurrent FOLFOX-RT?
The NCCN guidelines explicitly state: "The use of agents other than fluoropyrimidines are not recommended concurrently with RT" 1. This is because:
- Oxaliplatin concurrent with radiation significantly increases toxicity without proven survival benefit in the rectal cancer setting
- Standard concurrent agents are limited to fluoropyrimidines (5-FU or capecitabine) 1
- FOLFOX is reserved for the systemic treatment phases (before and/or after chemoRT)
When FOLFOX Might Be Used Without RT
Recent data from the PROSPECT trial showed that in carefully selected patients with T2N1-2 or T3N0-2 rectal cancer (candidates for sphincter-sparing surgery, ≤4 nodes, up to 1 cm), neoadjuvant FOLFOX alone (without radiation) achieved similar disease-free survival to chemoRT, with only 9.1% requiring subsequent preoperative chemoRT 3. However, this requires careful patient selection and is not universally applicable.
Clinical Context Matters
For Metastatic Rectal Cancer with Synchronous Metastases
In patients with resectable synchronous metastases, the approach differs:
- Combination chemotherapy (FOLFOX or FOLFIRI) for 2-3 months
- Then consider continuous IV 5-FU/pelvic RT or capecitabine/RT
- Followed by staged or synchronous resection 1, 4
For Colon Cancer (Not Rectal)
FOLFOX is used as adjuvant chemotherapy after surgery for colon cancer, not concurrently with radiation 5. Radiation is rarely used in colon cancer except for specific situations (T4 tumors, positive margins).
Key Pitfalls to Avoid
- Do not give oxaliplatin concurrently with pelvic radiation - this dramatically increases acute toxicity (diarrhea, hematologic toxicity) without proven benefit
- Do not confuse the TNT approach (sequential therapy) with true concurrent administration
- Patient selection is critical - not all rectal cancers require radiation; some T2-3 tumors may be treated with FOLFOX alone if carefully selected 3
Bottom Line Algorithm
For standard locally advanced rectal cancer:
- Give FOLFOX (4-6 cycles) → then 5-FU or capecitabine concurrent with RT (50 Gy) → surgery → additional FOLFOX
- OR give 5-FU/capecitabine concurrent with RT first → then FOLFOX → surgery → additional FOLFOX
Never give oxaliplatin-containing regimens (FOLFOX) simultaneously with pelvic radiation as standard practice.